Technical Analysis for ACXP - Acurx Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -1.52% | |
| Wide Bands | Range Expansion | -1.52% | |
| Outside Day | Range Expansion | -6.73% | |
| Wide Bands | Range Expansion | -6.73% | |
| Gapped Up | Strength | -6.73% | |
| Inside Day | Range Contraction | -10.60% |
| Alert | Time |
|---|---|
| Down 3% | about 17 hours ago |
| Down 2 % | about 17 hours ago |
| Possible NR7 | about 18 hours ago |
| 20 DMA Resistance | about 21 hours ago |
| Up 3% | about 22 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2024
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Care Antibiotics Bacterial Infections Staphylococcus Aureus Methicillin Gram Positive Bacteria Vancomycin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Care Antibiotics Bacterial Infections Staphylococcus Aureus Methicillin Gram Positive Bacteria Vancomycin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.82 |
| 52 Week Low | 1.17 |
| Average Volume | 76,241 |
| 200-Day Moving Average | 2.89 |
| 50-Day Moving Average | 2.26 |
| 20-Day Moving Average | 1.99 |
| 10-Day Moving Average | 2.09 |
| Average True Range | 0.18 |
| RSI (14) | 41.86 |
| ADX | 18.7 |
| +DI | 17.38 |
| -DI | 22.05 |
| Chandelier Exit (Long, 3 ATRs) | 1.80 |
| Chandelier Exit (Short, 3 ATRs) | 2.05 |
| Upper Bollinger Bands | 2.32 |
| Lower Bollinger Band | 1.66 |
| Percent B (%b) | 0.42 |
| BandWidth | 32.95 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.019 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.14 | ||||
| Resistance 3 (R3) | 2.14 | 2.09 | 2.10 | ||
| Resistance 2 (R2) | 2.09 | 2.04 | 2.08 | 2.09 | |
| Resistance 1 (R1) | 2.01 | 2.01 | 1.99 | 2.01 | 2.08 |
| Pivot Point | 1.96 | 1.96 | 1.94 | 1.95 | 1.96 |
| Support 1 (S1) | 1.88 | 1.91 | 1.86 | 1.88 | 1.80 |
| Support 2 (S2) | 1.83 | 1.88 | 1.82 | 1.79 | |
| Support 3 (S3) | 1.75 | 1.83 | 1.78 | ||
| Support 4 (S4) | 1.75 |
